CN103394043A - Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst - Google Patents
Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst Download PDFInfo
- Publication number
- CN103394043A CN103394043A CN2013103560975A CN201310356097A CN103394043A CN 103394043 A CN103394043 A CN 103394043A CN 2013103560975 A CN2013103560975 A CN 2013103560975A CN 201310356097 A CN201310356097 A CN 201310356097A CN 103394043 A CN103394043 A CN 103394043A
- Authority
- CN
- China
- Prior art keywords
- group
- nodules
- breast
- treatment
- paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst, and relates to a novel use of stasis-removing paste for nodules of breast. The application of the paste in for treatment of primary dysmenorrheal is as follows: applying the stasis-removing paste for nodules of breast to the yin chiao acupoint; starting to apply three days before menstruation, once a day for one paste for over 12 hours; and applying till the fourth day of menstruation. The application of the paste in treatment of ovarian cyst: applying the stasis-removing paste for nodules of breast to the yin chiao acupoint once a day for one paste for over 12 hours; and continuously applying for 28 days. The stasis-removing paste for nodules of breast disclosed by the invention is free from toxic and side effects and can be used for treating primary dysmenorrheal, so that pain symptom of the cured patients are completely relieved. Pain of the patients with improvement of the disease is alleviated. The patients are normal in menstrual blood volume, and the menstrual cycle is regular and normal. The stasis-removing paste for nodules of breast is used for treating ovarian cyst, so that pains on the lower abdomen, waist and two ribs of the cured patients disappear, menstruation has already come in medium volume, and lump disappear through B-ultrasonic reexamination. Pains on the lower abdomen, waist and two ribs of the patients with improvement of the disease disappear or are alleviated.
Description
Technical field
The present invention relates to the new purposes of eliminating stagnation nodules of the breast cream.
Background technology
[nomenclature of drug]
Adopted name: eliminating stagnation nodules of the breast cream
The Chinese phonetic alphabet: San jie Ru pi Gao
Eliminating stagnation nodules of the breast cream
[composition] Rhizoma Curcumae, Rhizoma Curcumae Longae, Semen Impatientis, Radix Semiaquilegiae, Semen Momordicae, the Radix Angelicae Dahuricae.
The medicated core of [character] this product is rectangle, yellow or brown color; Gas is fragrant.
[former function cures mainly] promoting flow of QI and blood, mass dissipating and swelling eliminating.Be used for the caused by energy stagnation and blood stasis nodules of the breast, disease is seen lump in breast, and companion's mastalgia mostly is distending pain, alters pain or twinge, and fullness and distention in the chest and hypochondrium, increase and decrease with menstrual cycle and emotion changes, dimly red tongue or ecchymosis, stringy pulse or hesitant pulse; Above-mentioned patient is seen in cystic hyperplasia of breast.
The heavy 7g of [specification] every subsides
[usage and dosage] external, first clean the skin affected part and wipe away driedly, then lining paper on plaster thrown off, and medicated core aimed at affected part stick.Paste, 1 time on the one, can stick continuously 28 days for one time 1.
Skin allergy can appear in [untoward reaction] small number of patients, and disease is seen skin pruritus, the point-like erythema.
[taboo] (1) contraindication in pregnancy.
(2) damaged skin forbidding.
[points for attention] (1) this product contains toxic component, please uses under physician guidance.
(2) the allergic constitution person is cautious use of.
(3) in medication, the local skin allergy sufferers is stopped using.
[storage] sealing, put shady and cool place (being no more than 20 ℃).
The multiple aluminium-plated bag of [packing] OPP.Every box-packed 3 paste.
[effect duration] 36 months.
The national drug standards YBZ05302004-2008Z of [operative norm] State Food and Drug Administration
The accurate word Z20040073 of [authentication code] traditional Chinese medicines
[manufacturing enterprise] enterprise name: Heilungkiang crane Xiang Pharmaceutical Co
As seen above-mentioned, eliminating stagnation nodules of the breast cream is used for the treatment of mastopathy at present.
Primary dysmenorrhea, be menstrual phase pain but there is no organic disease periodically, and its definite cause of disease is still not clear so far, this syndrome of the theoretical energy of neither one best explain, be one of modal symptom of gynecological patient, affected normal activity, and need Drug therapy.At present main Therapeutic Method is to use NSAID (non-steroidal anti-inflammatory drug) or the conditioning that takes traditional Chinese medicine, but have side effect greatly and Chinese medicine take inconvenience, the problem of making troubles to Working Life.
Ovarian cyst, refer to the benign tumor of ovary, is modal gynaecopathia.Can betide any female age, take period of duration as common.How the common non-evident sympton of patient, chance on when having a medical check-up.PD is slower clinically, with the slow increase of cyst, the performances such as menoxenia, abdominal distention stomachache is often arranged.When these symptoms were more serious, the probability that the women suffers from ovarian cyst was higher, and the pernicious probability of suffering from ovarian cancer of pathological changes and harm just larger.At present main Therapeutic Method is operation or the conditioning that takes traditional Chinese medicine, but have side effect greatly and Chinese medicine take inconvenience, the problem of making troubles to Working Life.
Summary of the invention
The object of the invention is to provide the application of eliminating stagnation nodules of the breast cream in primary dysmenorrhea and ovarian cyst treatment.
The application of eliminating stagnation nodules of the breast cream in the primary dysmenorrhea treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and menstruation started to stick in front 3 days, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.
The application of eliminating stagnation nodules of the breast cream in the ovarian cyst treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks continuously 28 days.
The application of eliminating stagnation nodules of the breast cream of the present invention in primary dysmenorrhea and ovarian cyst treatment, the treatment primary dysmenorrhea, recovery from illness patient's pain symptom is alleviated fully; Sb.'s illness took a favorable turn patient's pain relief, the lower abdomen dull pain of only suddenly feeling menstrual period or light-duty dysmenorrhea is arranged; Patient's menstrual blood volume is normal, menstrual cycle rule and normal.Treatment ovarian cyst, recovery from illness patient's lower abdomen, waist and pain in the hypochondrium disappear, menstruation extremely, measure medium, through the disappearance of B ultrasonic check lump; Sb.'s illness took a favorable turn patient's lower abdomen, waist and pain in the hypochondrium disappear or alleviate, the rare clot of menstruation, and lump dwindles more than 1/3～2/3.
The application of eliminating stagnation nodules of the breast cream of the present invention in primary dysmenorrhea and ovarian cyst treatment, for existing medicine eliminating stagnation nodules of the breast cream has been opened up new purposes, and have no side effect, the clinic application.
The specific embodiment
The specific embodiment one: the application of present embodiment eliminating stagnation nodules of the breast cream in the primary dysmenorrhea treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and menstruation started to stick in front 3 days, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.
The nodules of the breast of eliminating stagnation described in present embodiment cream, composition and preparation method are referring to patent " ointment for dispersing breast nodules, the patent No.: ZL200410043648.3, the applying date: 2004.6.23 ".
The nodules of the breast of eliminating stagnation described in present embodiment cream is applied to treat primary dysmenorrhea:
Function: promoting flow of QI and blood, mass dissipating and swelling eliminating.
Cure mainly: dysmenorrhea, disease is seen distention and pain in the lower abdomen before or during menstruation, pain with tenderness or by do not subtract, amenorrhea, postpone, Hypomenorrhea, blockage of menstruation, the menstruation color is dim, or accompanies clot, body of the tongue is dim or ecchymosis petechia, deep and stringy pulse arranged.
Medication and Therapeutic Method: be affixed on Yinjiao point (one-inch place under umbilicus), menstruation started to stick in front 3 days, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.
The specific embodiment two: the application of present embodiment eliminating stagnation nodules of the breast cream in the ovarian cyst treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks continuously 28 days.
The nodules of the breast of eliminating stagnation described in present embodiment cream, composition and preparation method are referring to patent " ointment for dispersing breast nodules, the patent No.: ZL200410043648.3, the applying date: 2004.6.23 ".
The nodules of the breast of eliminating stagnation described in present embodiment cream is applied to treat ovarian cyst:
Function: promoting flow of QI and blood, mass dissipating and swelling eliminating.
Cure mainly: ovarian cyst, disease see that few abdomen one side or bilateral have lump, and dysmenorrhea shortens, through measuring even amenorrhea lower abdomen pain of rareness menstrual period, and lower abdomen is uncomfortable, the soreness of waist, and leucorrhea abnormal, tongue has petechia.
Medication and Therapeutic Method: be affixed on Yinjiao point (one-inch place under umbilicus), every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks continuously 28 days.
It is as follows that in present embodiment, eliminating stagnation nodules of the breast cream is applied to treat the primary dysmenorrhea pharmacodynamic experiment:
1. experiment material
1.1 laboratory animal: Wistar rat, body weight 200 ± 20g, female unpregnancy, Changchun hundred million these laboratory animal technology Co., Ltds, the quality certification: SCXK (Ji) 2011-0004.
1.2 experimental drug and reagent:
(1) eliminating stagnation nodules of the breast cream, composition is: Rhizoma Curcumae, Rhizoma Curcumae Longae, Semen Impatientis, Radix Semiaquilegiae, Semen Momordicae, the Radix Angelicae Dahuricae; The buff paste, crane Xiang Pharmaceutical Co provides by Heilungkiang, lot number: 120504.
(2) reference substance substrate, be Cera Flava Oleum Sesami isometric(al) (1:1) mixture, and crane Xiang Pharmaceutical Co provides by Heilungkiang.
(3) sodium chloride injection, Tri-Lion Pharmaceutical Co., Ltd., Harbin, product batch number: 111020C5.
(4) progynova (estradiol valerate), provided lot number: B01007102 by Bayer Healthcare.
(5) oxytocin inj, the second hormone factory provides by Ningbo, lot number: 110251669.
(6) ethanol: crane city, Qiqihaer City disinfectant factory, authentication code: No. 100001st, the accurate word (2002) of black powder.
(7) compound recipe alcohol disinfection solution: the two crane sterile products development corporation, Ltd.s in Qiqihaer City, authentication code: defend No. 0160th, the word (2007) of disappearing.
(8) dinoprost (PGF2 α), ELISA detection kit, R﹠amp; D Systems.
(9) PGE2 (PGE2), ELISA detection kit, R﹠amp; D Systems.
1.3 experiment equipment:
HFsafe 1500/C type superclean bench Shanghai Lishen Scientific Equipment Co., Ltd.
AL204 type electronic analytical balance Britain Mettler Toledo
PL602-S type electronic scale Britain Mettler Toledo
DY89-I type electric driven glass refiner Ningbo Xin Zhike device institute
DGX-9143B-1 electric drying oven with forced convection Shanghai Fuma Experiment Equipment Co., Ltd.
Microfuge 18 Centrifuge centrifuge Germany Beckman Coulter
DSX-280B type pressure steam sterilizer Shenan Medical Appliances Factory, Shanghai
HHS11 type electric-heated thermostatic water bath Shanghai leap medical apparatus and instruments factory
Anthos 2010 microplate reader Anthos Labtec Instrument
Micropipettor Germany Eppendorf
HT2 microplate reader Zhengzhou rich plug biological engineering company limited
2. experimental technique:
2.1 experiment grouping
Get 48 of the female Sexual health wistar of unpregnancy rats, body weight 180～220g, be divided into dosage group in eliminating stagnation nodules of the breast cream high dose group, eliminating stagnation nodules of the breast cream, eliminating stagnation nodules of the breast cream low dose group, excipient matched group, blank group, model group, totally 6 groups at random.
2.2 modeling
Preparation estradiol valerate injection, getting 32 tablets of progynova tablets on the 1st day is put in mortar and is crushed to the Powdered 12ml of adding sodium chloride injection, the 2nd day～the 9th day photograph said method got 16 progynovas and is dissolved in the 12ml sodium chloride injection, and the 10th day photograph said method got 32 progynovas and be dissolved in the 12ml sodium chloride injection.Except the blank group, each treated animal equal every day of lumbar injection estradiol valerate, continuous 10 days, 0.3ml/ of injection (wherein every 0.3ml solution contains progynova 0.8mg) in the 1st day, 0.3ml/ of injection (wherein every 0.3ml solution contains progynova 0.4mg) in the 2nd day～the 9th day, 0.3ml/ of injection (wherein every 0.3ml solution contains progynova 0.8mg) in the 10th day.
2.3 dosage and route of administration
Eliminating stagnation nodules of the breast cream high dose group, middle dosage group, low dose group give respectively eliminating stagnation nodules of the breast cream 2.52g/kg, 1.26g/kg, 0.63g/kg, and the excipient matched group gives excipient 2.52g/kg.The injection estradiol valerate after the 5th day, is taken off the hair of each group rat abdomen with shaving mao machine, loses hair or feathers and starts to smear corresponding medicine in rear 24 hours, apply with oilpaper and gauze after coating, and fix the outer housing gauze screen with the nonirritant transparent rubberized fabric, in case sting food, be administered once every day.Continuous 6 days.
Each organizes rat in last injection estradiol valerate 24h, except the blank group, and after all the other each groups are smeared medicine 45min, lumbar injection oxytocin 2u/, writhing number of times in the incubation period of the appearance writhing response of each animal of immediate record and 30min.The data obtained is carried out statistical procedures.
2.4 draw materials
Each carries out the rat eye socket and gets blood 3ml after organizing rat injection oxytocin 1h, and 2500 turn/min, centrifugal 15min, centrifuging and taking serum ,-20 ℃ of preservations.
Get after blood uterus is dissected and isolated to each group rat, with electronic analytical balance, accurately weigh after the weight in wet base in uterus, clip uterine cancer cell 4g, put into the duroplasts homogenate tube, with refiner, is prepared into uterus homogenate.
2.5 index detects
2.5.1 with the ELISA method press the test kit operating instruction detect dinoprost in serum and uterus homogenate (content of (PGF2 α), operating procedure is as follows:
1. open the ELISA detection kit of P of Rats GF2 α, by operating instruction, required reagent is fully mixed.Avoid making liquid to produce a large amount of foams, so that add a large amount of bubbles, the error while increasing application of sample during application of sample.
2. will use in advance standard substance after the standard substance diluted by micropipettor, and add in the gauge orifice of 50 μ l, concentration is respectively 800,400,200,100,50,25,0pg/ml; To add in the product to be tested hole of 50 μ l with the testing sample after the sample diluting liquid dilution.The every hole of gauge orifice and product to be tested hole adds the biotin labeling antibody of 50 μ l immediately again, covers template, and vibration mixes gently, 37 ℃ of incubation 1h.
3. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
4. every hole adds affine chain enzyme-HRP of 60 μ l, and vibration mixes gently, 37 ℃ of incubation 30min.
5. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
6. every hole adds substrate A, each 50 μ l of B, and vibration mixes gently, 37 ℃ of incubation 10min.Avoid illumination.
7. take out ELISA Plate, add rapidly 50 μ l stop buffers, add after stop buffer measurement result immediately.
8. measure the OD value in each hole at 450nm wavelength place.
Detect the content of prostaglandin PGE2 (PGE2) in serum and uterus homogenate 2.5.2 with the ELISA method, press the test kit operating instruction, operating procedure is as follows:
1. open the ELISA detection kit of P of Rats GE2, by operating instruction, required reagent is fully mixed.Avoid making liquid to produce a large amount of foams, so that add a large amount of bubbles, the error while increasing application of sample during application of sample.
2. will use in advance standard substance after the standard substance diluted by micropipettor, and add in the gauge orifice of 50 μ l, concentration is respectively 800,400,200,100,50,25,0pg/ml; To add in the product to be tested hole of 50 μ l with the testing sample after the sample diluting liquid dilution.The every hole of gauge orifice and product to be tested hole adds the biotin labeling antibody of 50 μ l immediately again, covers template, and vibration mixes gently, 37 ℃ of incubation 1h.
3. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
4. every hole adds affine chain enzyme-HRP of 60 μ l, and vibration mixes gently, 37 ℃ of incubation 30min.
5. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
6. every hole adds substrate A, each 50 μ l of B, and vibration mixes gently, 37 ℃ of incubation 10min.Avoid illumination.
7. take out ELISA Plate, add rapidly 50 μ l stop buffers, add after stop buffer measurement result immediately.
8. measure the OD value in each hole at 450nm wavelength place.
2.6 statistical procedures
Application SPSS17.0 statistical analysis software carries out statistical analysis, and experimental result is with mean ± standard deviation
Expression, the comparison of group difference is carried out in the t check, and showing property level of difference is take 0.05 and 0.01 as standard.
3. experimental result:
3.1 the impact of eliminating stagnation nodules of the breast cream on the rat uterus coefficient, in Table 1.
The impact of table 1 eliminating stagnation nodules of the breast cream on the rat uterus coefficient
| Group | Dosage (g/kg) | Number of animals (n) | Uterus coefficient (mg) |
| High dose group | 2.52 | 8 | 2.78±0.49*# |
| Middle dosage group | 1.26 | 8 | 2.76±0.36*# |
| Low dose group | 0.63 | 8 | 2.93±0.39*# |
| Vehicle group | 2.52 | 8 | 2.45±0.73*# |
| The blank group | 0 | 8 | 1.66±0.43 |
| Model control group | 0 | 8 | 2.76±0.50* |
Annotate: each dosage group and model control group compare, #P〉0.05, each dosage group and blank group compare, * P＜0.05.
Result shows: model group blank group relatively, uterus index content obviously raises, significant difference (P＜0.05) is arranged, and high, medium and low administration group, vehicle group and model group comparison there was no significant difference (P〉0.05), explanation may exert an influence to estrogen level because of diethylstilbestrol, the effect that increases sexual organ's weight is arranged, and eliminating stagnation nodules of the breast cream has no significant effect to this uterus weight in wet base.
3.2 the impact of eliminating stagnation nodules of the breast cream on rat writhing pain, in Table 2.
The impact of table 2 eliminating stagnation nodules of the breast cream on rat writhing pain
| Group | Writhing number of times in 30min | The writhing incidence rate |
| Eliminating stagnation nodules of the breast cream high dose group | 5.25±2.12** | 5/8(62.5%) |
| Dosage group in eliminating stagnation nodules of the breast cream | 7.50±2.14** | 6/8(75%) |
| Eliminating stagnation nodules of the breast cream low dose group | 9.50±2.40** | 6/8(75%) |
| Vehicle group | 17.38±2.67 | 8/8(100%) |
| The blank group | 0±0** | 0 |
| Model control group | 18.38±4.81 | 8/8(100%) |
Annotate: compare * P＜0.05, * * P＜0.01 with model control group.
Result shows: because oxytocin injection is not without writhing response, model group writhing increased frequency, difference have significant (P＜0.01) except blank group rat.High dose group, middle dosage group and low dose group and model group comparing difference all have significant (P＜0.01), and vehicle group and model group comparative result demonstration property difference (P〉0.05) not illustrates that eliminating stagnation nodules of the breast cream has the effect of relieving spasm to stop pain.
3.3 the impact that eliminating stagnation nodules of the breast cream changes hormonal readiness in blood plasma and uterus homogenate.
3.3.1 Prostaglandin PGE2, table 3
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and Prostaglandin PGE2 reduces, and difference has significant (P＜0.01), and the modeling success is described.Relatively, though Prostaglandin PGE2 has rising, difference does not have significant (P〉0.05), illustrate that high dose group, middle dosage group and the effect of low dose group adjusting Prostaglandin PGE2 are not obvious for high dose group, middle dosage group and low dosage and model group.In tissue, model group compares with blank group, and Prostaglandin PGE2 reduces, and difference has significant (P＜0.05), and the modeling success is described.Relatively, Prostaglandin PGE2 raises for high dose group and model group, and difference has significant (P＜0.01), illustrates that high dose group is regulated the Prostaglandin PGE2 effect obvious.Middle dosage group and low dosage and model group comparing difference have significant (P＜0.05), and Prostaglandin PGE2 raises, and in explanation, dosage group and low dose group have the effect of the Prostaglandin PGE2 of adjusting, but do not have high dose group good.
3.3.2 Prostaglandin PGF2 alpha table 4
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and Prostaglandin PGF2 alpha raises, and difference has significant (P＜0.01), and the modeling success is described.Relatively, Prostaglandin PGF2 alpha reduces for high dose group, middle dosage group and low dosage and model group, but difference does not have significant (P＜0.05), illustrates that high dose group, middle dosage group and low dose group are regulated the Prostaglandin PGF2 alpha effect not obvious.In tissue, model group compares with blank group, and Prostaglandin PGF2 alpha raises, and difference has significant (P＜0.05), and the modeling success is described.Relatively, Prostaglandin PGF2 alpha reduces for high dose group and model group, and difference has significant (P＜0.01), illustrates that high dose group has the effect of the Prostaglandin PGF2 alpha of adjusting.Relatively, Prostaglandin PGF2 alpha reduces for middle dosage group and low dosage and model group, but difference does not have significant (P〉0.05), and it is not obvious that in explanation, dosage group and low dose group are regulated the Prostaglandin PGF2 alpha effect.
3.3.3PGF2 α/PGE2 table 5
| Ratio | Serum | Tissue |
| High dose | 0.95±0.79* | 0.83±0.31** |
| Middle dosage | 1.23±0.68 | 1.11±0.47* |
| Low dosage | 1.40±0.68 | 1.15±0.17** |
| Excipient | 1.86±1.16 | 1.13±0.58 |
| Model group | 1.79±0.85## | 1.58±0.31# |
| Blank group | 0.41±0.03 | 0.81±0.23 |
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and PGF2 α/PGE2 ratio raises, and difference has significant (P＜0.01), and the modeling success is described.Relatively, PGF2 α/PGE2 ratio reduces for high dose group and model group, and difference has significant (P＜0.05), and high dose group reduction PGF2 is described, and α/PGE2 ratio is obvious.Though middle dosage group and low dose group reduce PGF2 α/PGE2 ratio and reduce, difference does not have significant (P〉0.05), and in explanation, α/PGE2 ratio is not obvious with low dose group reduction PGF2 for dosage.In tissue, model group compares with blank group, and PGF2 α/PGE2 ratio raises, and difference has significant (P＜0.05), and the modeling success is described.High dose group, middle dosage group and low dose group and model group are relatively, PGF2 α/PGE2 ratio all reduces, difference has significant (P＜0.01, P＜0.05, P＜0.01), and high dose group, middle dosage group and low dose group reduction PGF2 are described, and α/effect of PGE2 ratio is obvious.
4 conclusions
(1) this Success in Experiment has copied the primary dysmenorrhea rat model, and its serum prostaglandin level and primary dysmenorrhea are closely similar.Therefore, think that this model is a kind of more satisfactory primary dysmenorrhea model.
(2) eliminating stagnation nodules of the breast cream reduces rat writhing number of times, suppresses uterus and acutely shrinks, and improves the dysmenorrhea symptom.
(3) eliminating stagnation nodules of the breast cream can reduce the content of Dysmenorrhea Rats uterine smooth muscle PGF2 α, the content of PGE2 in rat uterus simultaneously raises, and reduce and reduction PGF2 α/PGE2, can suppress the spastic contraction of uterine smooth muscle, the expansion blood vessel, increase the hemoperfusion amount, improve microcirculation, thereby dysmenorrhea is eased.
The generation of dysmenorrhea is relevant with the content of development and the interior PGF2 α of body and PGE2.And the endometrium generation is different to the effect of non-gravid uterus from PGE2 with the PGF2 α that discharges, PGE2 can suppress the spontaneous activity of uterine smooth muscle, PGF2 α impels uterine myometrium, uterine blood flow lowers, the PGF2 α of high concentration acts on the PGF2 α receptor on spiral petty action astillen, causes the spastic contraction of uterine smooth muscle.if endometrium produces and release PGF2 α is too much, PGF2 α/PGE2 ratio rises, cause the spastic contraction of uterine smooth muscle to increase the weight of, show as the uterus muscular hypertonia, shrinkage amplitude increase etc., uterine blood flow is reduced, the uterus ischemia, and the pelvic nerve tip is to chemistry, physical stimulation threshold of pain attenuating etc., abnormal uterine shrinks, ischemia and anoxia, acidic metabolite is piled up in the flesh layer and causes dysmenorrhea, so reduce the secretion of PGF2 α value, can effectively suppress the spastic contraction of uterine smooth muscle, improve blood circulation, alleviate ischemic state, thereby reach the effect of pain relieving.And can suppress the spontaneous activity of uterine smooth muscle by rising PGE2 value, and make smooth muscle loosening, play the effect of pain relieving.Can effectively suppress the spastic contraction of uterine smooth muscle therefore reduce PGF2 α/PGE2 value, increase blood flow, improve the ischemia anaerobic condition, thus the performance analgesic effect.
Therefore, in present embodiment, eliminating stagnation nodules of the breast cream can reduce the content of Dysmenorrhea Rats uterine smooth muscle PGF2a, the content of PGE2 in the rat uterus that raises simultaneously, and reduce PGF2 α/PGE2 value, in sum, in present embodiment, eliminating stagnation nodules of the breast cream has therapeutical effect for primary dysmenorrhea.
In present embodiment, eliminating stagnation nodules of the breast cream is applied to primary dysmenorrhea patient's clinical trial:
Adopt random method, 100 routine cyclomastopathy are divided into 2 groups at random with the dysmenorrhea patient.Matched group 50 examples are treated with oral Rupisanjie capsule associating ease pill, and 45d is 1 course for the treatment of.Treatment group in the application Rupisanjie capsule, is used eliminating stagnation nodules of the breast cream local topical instead for dysmenorrhea.Eliminating stagnation nodules of the breast cream, be affixed on Yinjiao point (one-inch place under umbilicus), and menstruation started to stick in front 3 days, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.Two groups of medications were added up curative effect after 90 days.Treatment group is in the treatment cyclomastopathy as a result, and dysmenorrhea has obtained effective treatment.Conclusion eliminating stagnation nodules of the breast cream can effectively be treated dysmenorrhea, and has no side effect, the clinic application.
1 data and method
1.1 data
This group 100 examples are all from OILFIELDS GENEROL HOSPITAL IN DAGING breast disease special outpatient clinic, and the age is at 16～46 years old, 30 years old mean age; The course of disease 2 months～5 years.Be divided at random treatment group 50 example and matched group 50 examples, learn and process without significant difference (P＞0.05) by statistics on age, the course of disease, have comparability for 2 groups.
1.2 diagnostic criteria
Dysmenorrhea shows as menstrual period or there are serious lower abdominal pain, the soreness of waist etc. in its front and back, affects the symptom of work and life.The patient who suffers from cyclomastopathy occur together dysmenorrhea and menoxenia more.
1.3 Therapeutic Method
1.3.1 matched group.With the treatment of Rupisanjie capsule associating ease pill.The Rupisanjie capsule consumption: oral, each 4, tid; 45d is 1 course for the treatment of.Adapted ease pill usage: oral. 8 balls once, 3 times on the one.
1.3.2 treatment group in the treatment of the control group Rupisanjie capsule, is used eliminating stagnation nodules of the breast cream instead, the Rupisanjie capsule consumption: each 4, every day 3 times; 45d is 1 course for the treatment of, eliminating stagnation nodules of the breast cream usage: local Yinjiao point external, be affixed on Yinjiao point (one-inch place under umbilicus), and menstruation started to stick in front 3 days, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.
2 results
2.1 criterion of therapeutical effect
Judge with reference to " new Chinese medicine guideline of clinical investigations " relevant criterion
2.2 clinical efficacy is in Table 6
2.3 conclusion
Treatment group treatment dysmenorrhea total effective rate is 96%; Treatment of control group dysmenorrhea total effective rate is 72%.The treatment group therapeutic effect is better than matched group.
2.3 safety evaluatio
Do not find adverse events in two groups of observation processes, external-applied ointment skin allergy 5 examples occur, recover after drug withdrawal.
Knot nodules of the breast cream reaches 4-6CM by transdermal drug delivery system 1-2 hour property of medicine transdermal, makes medicine directly act on rapidly affected area, plays the fast treating effect.
Result shows that eliminating stagnation nodules of the breast cream treatment dysmenorrhea is safe and effective, is worth application.
It is as follows that in present embodiment, eliminating stagnation nodules of the breast cream is applied to treat the ovarian cyst pharmacodynamic experiment:
[experiment purpose], by setting up the endometriosis rat model, inquires into therapeutical effect and the effect of eliminating stagnation nodules of the breast cream to ovarian cyst.
[experimental technique] adopts the operation transplantation method to set up rat experiment gamogenetic egg nest cyst model, adopt radioimmunology to detect the content of estrogen (E2), progestogen (P), interstitialcellstimulating hormone (ICSH) (LH), flitropin (FSH) in serum and uterine cancer cell, and adopt the ELASE method to detect Connective Tissue Growth Factor (CTGF) content; Simultaneously, observe the morphologic variation of ovarian cyst rat uterus.
[experimental result] eliminating stagnation nodules of the breast cream all has different lower mediation inhibitory action to modeling rat estrogen (E2), progestogen (P), to interstitialcellstimulating hormone (ICSH) (LH), have upper mediation facilitation, with the model group comparing difference, significant (P＜0.05) is arranged; This medicine has the effect of reduction Connective Tissue Growth Factor (CTGF) content simultaneously, and each dosage group and model control group comparing difference have significant (P＜0.05).
[experiment conclusion] eliminating stagnation nodules of the breast cream has therapeutical effect to ovarian cyst.
1 experiment material
1.1 laboratory animal
The Wistar rat, body weight 200 ± 20g, female unpregnancy, Changchun hundred million these laboratory animal technology Co., Ltd qualitys certification: SCXK (Ji) 2011-0004.
1.2 Experimental agents and reagent
(1) eliminating stagnation nodules of the breast cream, composition is: Rhizoma Curcumae, Rhizoma Curcumae Longae, Semen Impatientis, Radix Semiaquilegiae, Semen Momordicae, the Radix Angelicae Dahuricae; The buff paste, crane Xiang Pharmaceutical Co provides by Heilungkiang, lot number: 120504.
(2) reference substance substrate, be Cera Flava Oleum Sesami isometric(al) (1:1) mixture, and crane Xiang Pharmaceutical Co provides by Heilungkiang.
(3) sodium chloride injection, Tri-Lion Pharmaceutical Co., Ltd., Harbin, product batch number: 111020C5.
(4) ethanol: crane city, Qiqihaer City disinfectant factory, authentication code: No. 100001st, the accurate word (2002) of black powder.
(5) compound recipe alcohol disinfection solution: the two crane sterile products development corporation, Ltd.s in Qiqihaer City, authentication code: defend No. 0160th, the word (2007) of disappearing.
(6) estrogen, radioimmunoassay kits, the three-dimensional biological engineering Group Co.,Ltd in Weifang.
(7) progestogen, radioimmunoassay kits, the three-dimensional biological engineering Group Co.,Ltd in Weifang.
(8) interstitialcellstimulating hormone (ICSH), radioimmunoassay kits, the three-dimensional biological engineering Group Co.,Ltd in Weifang.
(9) flitropin, radioimmunoassay kits, the three-dimensional biological engineering Group Co.,Ltd in Weifang.
(10) Connective Tissue Growth Factor, ELISA detection kit, R﹠amp; D Systems.
1.3 key instrument
HFsafe1500/C type superclean bench Shanghai Lishen Scientific Equipment Co., Ltd.
AL204 type electronic analytical balance Britain Mettler Toledo
PL602-S type electronic scale Britain Mettler Toledo
DY89-I type electric driven glass refiner Ningbo Xin Zhike device institute
DGX-9143B-1 electric drying oven with forced convection Shanghai Fuma Experiment Equipment Co., Ltd.
Microfuge18Centrifuge centrifuge Germany Beckman Coulter
DSX-280B type pressure steam sterilizer Shenan Medical Appliances Factory, Shanghai
HHS11 type electric-heated thermostatic water bath Shanghai leap medical apparatus and instruments factory
Anthos2010 microplate reader Anthos Labtec Instrument
Micropipettor Germany Eppendorf
FJ-2003PS γ radiation immunity arithmometer Xi'an nuclear instrument factory
2 experimental techniques and step
2.1 modeling
Operating procedure:
(1) get rat, it carried out vagina come off and learn to check, continuous more than 4 times the rat of oestrous cycle rule just classify the modeling object as.
(2) with operating equipment, 4-0 chromium line in alcohol disinfecting, with pressure steam sterilizer sterilizing, put into the electric drying oven with forced convection drying after sterilizing completing, standby.
(3) get and be in estrous rat, with the dosage intraperitoneal injection of anesthesia rat of 10% chloral hydrate with 350mg/kg.
(4) after rat anesthesia, its back of the body position is fixed on the operation plate, abdominal part is shaved hair, 75% ethanol disinfection skin.
(5) make the long longitudinal incision of 2-3cm apart from pubic symphysis 1cm place on ventrimeson, exposure enters abdominal cavity behind abdominal cavity.
(6) choose the left side cornua uteri, peel off mesentery, ligation stage casing cornua uteri part and Mesenteric.
(7) excise approximately 12mm of ligation place cornua uteri, and repair superabundant fats around uterus, separate flesh layer and inner membrance, with its longitudinal incision.
(8) get one section approximately (0.5 multiply by 0.5) cm
2Inner membrance, make its superficial epithelium facing to right abdomen rich blood vessel place, and its four jiaos are fixed with 4-0 chromium suturing with thread management with abdominal wall muscle.
(9) use the normal saline flushing abdominal cavity, after the capable end of the uterus broken ends of fractured bone-end anastomosis, close abdomen, routine disinfection.
2.2 the judgement of modeling and inclusive criteria
In postoperative 4 weeks, Animal Anesthesia after performing the operation, open abdomen and observe the situation of transplanting the inner membrance growth, and modeling success standard is:
(1) graft forms pale red or kermesinus vesicle, and wall is thin, and the vesicle height is more than or equal to 2mm.
(2) transplant that stove is long-pending to be increased, be transparent nodositas, cryptomere, have supernatant liquid to gather, graft is covered by connective tissue and vascularization is arranged, and quality is soft.
(3) ovarian cyst is greater than more than 30mm.
2.3 experiment grouping
Choose 40 of the animals of modeling success, being divided at random is 5 groups, 8 every group, i.e. eliminating stagnation nodules of the breast cream high dose group, middle dosage group, low dose group, excipient matched group, model group, separately get 8 not the animal of modeling, as the blank group, amount to 6 groups.
2.4 dosage and route of administration
Eliminating stagnation nodules of the breast cream high dose group, middle dosage group, low dose group give respectively eliminating stagnation nodules of the breast cream 2.52g/kg, 1.26g/kg, 0.63g/kg, and the excipient matched group gives excipient 2.52g/kg.
With shaving mao machine, the hair of each group rat abdomen is taken off before test, lost hair or feathers and started to smear corresponding medicine in rear 24 hours, apply with oilpaper and gauze after coating, and with the nonirritant transparent rubberized fabric, fix, the outer housing gauze screen, single cage is raised, in case sting food, be administered once every day.Continuous 6 weeks.
2.5 draw materials
Next day after the last administration, eyeball is got blood 5ml, puts into centrifuge,, with the centrifugal 15min of 2500r/min, isolates serum, and is standby.After eyeball is got blood, with 75% ethanol routine disinfection skin of abdomen.Get the strong side cornua uteri stage casing of half animal, carry out pathological observation, it is standby that second half makes tissue homogenate.
2.6 index detects
2.6.1 radioimmunology
1. radioimmunology detects the content of serum and tissue homogenate estrogen (E2), and concrete steps are as follows:
(1) at first test tube is carried out label: the T(grand total), the NSB(non-specific binding), S
0(maximum combined) and S
1To S
5, the QC(quality-control product) and the U(sample), then in the following order the operation.
(2) add label 100 μ l in test tube T; Add respectively distilled water 100 μ l, zero standard 100 μ l, label 100 μ l in test tube NSB; Test tube S
0Middle zero standard 100 μ l, label 100 μ l, the antibody 100 μ l of adding respectively; Test tube S
1To S
5Add respectively standard substance 100 μ l, label 100 μ l, antibody 100 μ l; Add respectively quality-control product 100 μ l, label 100 μ l, antibody 100 μ l in test tube QC; Add respectively sample 100 μ l, label 100 μ l, antibody 100 μ l in test tube U.
(3) mix 37 ℃ of water-bath incubations 2 hours.
(4) except test tube T, all the other add respectively separating medium 500 μ l.
(5) fully mix, room temperature was placed 15 minutes, 4 ℃ of 3500r/min, and centrifugal 20 minutes, to inhale and abandon supernatant (except the T pipe), precipitate counting 1 minute, measure the radiocounting of each pipe precipitation on gamma counter.
2. detect the content of serum and tissue homogenate progestogen (P) with radioimmunology, concrete steps are as follows:
(1) at first test tube is carried out label: the T(grand total), the NSB(non-specific binding), S
0(maximum combined) and S
1To S
5, the QC(quality-control product) and the U(sample), then in the following order the operation.
(2) add label 100 μ l in test tube T; Add respectively zero standard 200 μ l, label 100 μ l in test tube NSB; Test tube S
0Middle zero standard 100 μ l, label 100 μ l, the antibody 100 μ l of adding respectively; Test tube S
1To S
5Add respectively standard substance 100 μ l, label 100 μ l, antibody 100 μ l; Add respectively quality-control product 100 μ l, label 100 μ l, antibody 100 μ l in test tube QC; Add respectively sample 100 μ l, label 100 μ l, antibody 100 μ l in test tube U.
(3) mix 37 ℃ of water-bath incubations 1 hour.
(4) except test tube T, all the other add respectively separating medium 500 μ l.
(5) fully mix, room temperature was placed 15 minutes, 4 ℃ of 3500r/min, and centrifugal 20 minutes, to inhale and abandon supernatant (except the T pipe), precipitate counting 1 minute, measure the radiocounting of each pipe precipitation on gamma counter.
3. detect the content of serum and tissue homogenate interstitialcellstimulating hormone (ICSH) (LH) with radioimmunology, concrete steps are as follows:
(1) get appropriate coated pipe label: S
0To S
5, the QC(quality-control product) and the U(sample), then in the following order the operation.
(2) S
0To S
5Add respectively standard substance 100 μ l, label 100 μ l; Add respectively quality controlled serum 100 μ l, label 100 μ l in test tube QC; Add respectively sample 100 μ l, label 100 μ l in test tube U.
(3) mix 37 ℃ of water-bath incubations 1 hour.
(4) inhale and abandon reactant liquor, with the cleaning mixture wash bags after dilution, managed twice, each 2ml, will blot clean liquid after each washing.
(5) measure the radiocounting of each pipe precipitation on gamma counter.
4. detect the content of serum and tissue homogenate flitropin (FSH) with radioimmunology, concrete steps are as follows:
(1) get appropriate coated pipe label: S
0To S
5, the QC(quality-control product) and the U(sample), then in the following order the operation.
(2) S
0To S
5Add respectively standard substance 50 μ l, label 100 μ l; Add respectively quality controlled serum 50 μ l, label 100 μ l in test tube QC; Add respectively sample 50 μ l, label 100 μ l in test tube U.
(3) mix 37 ℃ of water-bath incubations 1 hour.
(4) inhale and abandon reactant liquor, with the cleaning mixture wash bags after dilution, managed twice, each 2ml, will blot clean liquid after each washing.
(5) measure the radiocounting of each pipe precipitation on gamma counter.
2.6.2ELISA method
Press the test kit operating instruction with the ELISA method and detect Connective Tissue Growth Factor (CTGF) content in tissue homogenate.
1. open rat connective tissue growth factor ELISA detection kit, by operating instruction, required reagent is fully mixed.Avoid making liquid to produce a large amount of foams, so that add a large amount of bubbles, the error while increasing application of sample during application of sample.
2. will use in advance standard substance after the standard substance diluted by micropipettor, and add in the gauge orifice of 50 μ l, concentration is respectively 800,400,200,100,50,25,0pg/ml; To add in the product to be tested hole of 50 μ l with the testing sample after the sample diluting liquid dilution.The every hole of gauge orifice and product to be tested hole adds the biotin labeling antibody of 50 μ l immediately again, covers template, and vibration mixes gently, 37 ℃ of incubation 1h.
3. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
4. every hole adds affine chain enzyme-HRP of 60 μ l, and vibration mixes gently, 37 ℃ of incubation 30min.
5. get rid of liquid in hole, cleaning mixture is filled it up with in every hole, vibrates 30 seconds, gets rid of cleaning mixture, with absorbent paper, pats dry.Repeat this operation 3 times.
6. every hole adds substrate A, each 50 μ l of B, and vibration mixes gently, 37 ℃ of incubation 10min.Avoid illumination.
7. take out ELISA Plate, add rapidly 50 μ l stop buffers, add after stop buffer measurement result immediately.
8. measure the OD value in each hole at 450nm wavelength place.
2.7 statistical procedures
Application SPSS17.0 statistical analysis software carries out statistical analysis, and experimental result is with mean ± standard deviation
Expression, the comparison of group difference is carried out in the t check, and showing property level of difference is take 0.05 and 0.01 as standard.
3 experimental results
3.1 radioimmunology
3.1.1 estrogen is in Table 7
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and serum estradiol raises, and difference has significant (P＜0.05), and the modeling success is described; Relatively, serum estradiol reduces for high dose group and model group, and difference has significant (P＜0.05), illustrates that high dose group has the effect of the estrogen level of adjusting.Relatively, serum estradiol reduces for middle dosage group, low dose group and model group, though variant, no significant difference (P〉0.05), dosage group in explanation, that low dose group is regulated the estrogen level effect is not obvious.In tissue, model group compares with blank group, organizes estrogen to raise, and difference has significant (P＜0.05), and the modeling success is described; High dose group and model group relatively, organize estrogen to reduce, and difference has significant (P＜0.05), illustrate that high dose group has the effect of the estrogen level of adjusting.Middle dosage group, low dose group and model group relatively, organize estrogen to reduce, though variant, no significant difference (P〉0.05), dosage group in explanation, that low dose group is regulated the estrogen level effect is not obvious.
3.1.2 progestogen are in Table 8
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and serum progestational hormone raises, and difference has significant (P＜0.01), and the modeling success is described; Relatively, serum progestational hormone reduces for high dose group, middle dosage group and low dose group and model group, and difference has significant (P＜0.01), illustrates that high dose group, middle dosage group and low dose group all have the effect of the progesterone level of adjusting.In tissue, due to this radioimmunological kit for the normal concentration scope of the detection of progestogen between 0.50-200.00ng/ml, and in tissue the content of progestogen all lower than 0.50ng/ml, therefore do not show result.
3.1.3 interstitialcellstimulating hormone (ICSH) table 9
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, model group compares with blank group, and interstitialcellstimulating hormone (ICSH) reduces, and difference has significant (P＜0.05), and the modeling success is described; Each medication group and model group relatively, though interstitialcellstimulating hormone (ICSH) has rising trend, difference there are no significant meaning (P〉0.05), illustrate eliminating stagnation nodules of the breast cream to interstitialcellstimulating hormone (ICSH) in serum (LH) without obvious regulating action.In tissue, model group compares with blank group, and interstitialcellstimulating hormone (ICSH) reduces, and difference has significant (P＜0.05), and the modeling success is described; Relatively, interstitialcellstimulating hormone (ICSH) raises for high dose group and model group, and difference has significant (P＜0.05), illustrates that high dose group has the effect of the interstitialcellstimulating hormone (ICSH) of adjusting.Relatively, interstitialcellstimulating hormone (ICSH) raises for middle dosage group and low dose group and model group, though variant, and no significant difference (P〉0.05), it is not obvious that in explanation, dosage group and low dose group are regulated the interstitialcellstimulating hormone (ICSH) effect.
3.1.4 flitropin table 10
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: in serum, due to this radioimmunological kit for the normal concentration scope of the detection of flitropin between 1.00-160.00mlU/ml, and the content in the serum flitropin is all lower than 1.00mlU/ml, therefore do not show result.In tissue, relatively, flitropin reduces for model group and blank group, but difference does not have significant (P〉0.05), and this group data show model group does not have difference with blank group, so all the other groups are more nonsensical with model group.
3.2ELISA method table 11
| Group | Number of cases | Dosage | Connective Tissue Growth Factor (ng/ml) |
| High dose group | 8 | 2.52 | 0.35±0.08** |
| Middle dosage group | 8 | 1.26 | 0.21±0.11** |
| Low dose group | 8 | 0.63 | 0.36±0.21** |
| Vehicle group | 8 | 2.52 | 0.73±0.08** |
| Model control group | 8 | 0 | 0.97±0.24## |
| The blank group | 8 | 0 | 0.13±0.06 |
Notes: model group compares with blank group, #P＜0.05, and ##P＜0.01, each dosage group and model group compare, * P＜0.05, * * P＜0.01.
Result shows: model group compares with blank group, and Connective Tissue Growth Factor raises, and difference has significant (P＜0.01), and the modeling success is described; Relatively, Connective Tissue Growth Factor reduces for high dose group, middle dosage group and low dose group and model group, and difference has significant (P＜0.01), illustrates that high dose group, middle dosage group and low dose group all have the effect of the Connective Tissue Growth Factor of adjusting.
3.3 morphological change
3.3.1 Histomorphology
Normal group: mucosal epithelium is complete, and the flesh layer, placenta percreta is complete, boundary is clear, and in mucous layer, Interstitial cell is evenly distributed, and the inner membrance body of gland is abundant and complete, and lumen of gland is large.
Model group: Uterus wall thickens, and normal configuration is disorderly, and layering is unclear, and form is irregular.The inner membrance body of gland is rare, and the part lumen of gland is slightly large.
Treatment group (high, medium and low dosage, matched group): with the Interstitial cell Mild edema, body of gland quantity and blood vessel recover substantially, and lumen of gland is little, and the coating of inner membrance mucomembranous surface is cubical epithelium or simple squamous epithelium, the inner membrance attenuation.
Uterus is the target device palace of gonadal hormone, and sex hormone function can make its protein synthesis increase, vasodilation, permeability change in uterus, and uterus increases the intake of water, therefore can judge the gonadal hormone effect with the uterus coefficient.Have the receptor of multiple hormone and peptide class on uterus, their variation can cause the change of uterus shape and function.This experimental result shows, normal group shows as the Normal endometrium glandular epithelium and is column, and the inner membrance body of gland is abundanter, and lumen of gland is large.In model group, the endometrial gland epithelial cell of performance dystopy is column, and the inner membrance body of gland is more rare, and the part lumen of gland is larger.And in treatment group, endometriotic tissues body of gland quantity has increased slightly than model group, and lumen of gland is little, and the inner membrance mucomembranous surface is cubical epithelium or simple squamous epithelium, the inner membrance attenuation.
In sum, blank group is remarkable with the model group comparing difference, shows the modeling success.Treatment group and model group relatively, have the effect for the treatment of.Eliminating stagnation nodules of the breast cream can significantly increase body of gland and blood vessel quantity in rat uterus, and fibrous connective tissue reduces.Infer that thus medicine may directly act on uterus, promote the growth of rat uterus germinal epithelium, improve cell, body of gland and number of blood vessel, fibrous connective tissue is reduced, improve the endometrium state, alleviate metratrophia.Between treatment group, comparing difference is not remarkable, and relatively middle dosage group is better.Show that this medicine has certain nutrition uterus and improves the effect of its function.
4 conclusions
(1) this Success in Experiment has copied the ovarian cyst rat model, and this model is studied from aspects such as neuroendocrinology, morphologys, shows that level and the ovarian cyst of hormone in its serum and tissue is closely similar.Therefore, think that this model is a kind of animal model of more satisfactory ovarian cyst.
(2) eliminating stagnation nodules of the breast cream can reduce estrogenic content in serum and tissue, also can reduce the content of progestogen in serum, simultaneously, can improve the content of interstitialcellstimulating hormone (ICSH) in tissue, show that it can obviously improve the disorder of hormone,, by regulating the functional abnormal of hypothalamic-pituitary-ovarian axis, make multiple hormonal system functional rehabilitation in body.
(3) eliminating stagnation nodules of the breast cream reduces the content of Connective Tissue Growth Factor in serum, reduces the propagation of ovarian cyst cell and the generation of blood vessel.
(4) eliminating stagnation nodules of the breast cream can significantly increase body of gland and blood vessel quantity in the uterus of ovarian cyst rat, and fibrous connective tissue is reduced, and improves the endometrium state, alleviates metratrophia.
Ovary is as women's gonad, and the anatomical basis of its Function is the follicle of normal development in ovarian cortex and in and out of blood vessel and the nerve of hilum of ovary.Keep normal ovarian function, can make ovary keep good blood circulation and endocrine function.the paathogenic factor of ovarian cyst is likely abnormal due to the hypothalamic-pituitary-ovarian axis function, this theory thinks that the Hypothalamus-pituitary dysfunction is mainly manifested in the ovarian cyst patient too much LH secretion is arranged, aperiodicity changes and the LH peak goes out, and the secretion of FSH is normal or slightly low, thereby LH/FSH ratio increases, LH directly acts on the thecacells of ovary, by increasing the activity of side chain cracking P450c17a in cell, make thecacells in ovary produce too much androgen, thereby make ovarian cyst have influence on women's ovary built-in function, thereby affect the endocrine function of ovary, show as menoxenia.
Most scholars thinks, sex hormone level regulation often affects generation, the growth of muscular tumor, and the equilibrium condition between the hormone that ovary produces and various hormone is the tumorigenic influence factor of female reproductive system often.Study more as estrogen, progestogen, interstitialcellstimulating hormone (ICSH) and flitropin and some somatomedin.Some patients with ovarian tumor are often with cryptorrheic clinical symptoms.Think at present that these cryptorrheas are synthetic by ovarian tumor cell or the hormonosis of conversion suppresses or due to ovarian tumor Interstitial cell endocrine function strengthens.Ovary is the organ that secretes sex hormones, and ovary tissue Cancer sexually transmitted disease (STD) can secrete sex hormones after becoming too much; Because the Histology and Embryology of ovary is complicated, the tumor of generation is variation also, can produce some other hormone.This experiment, by the variation of research ovarian cyst hormone in vivo level, illustrates the therapeutical effect of eliminating stagnation nodules of the breast cream in present embodiment.
In sum, the function of eliminating stagnation nodules of the breast cream is a kind of integrally-regulated effect.No matter being to suppress ovarian cyst growth, adjustment gonad axis, recovering the balance of organism endocrine hormone, or improve body Hangzhoupro tumour immunity function etc., is all that eliminating stagnation nodules of the breast cream acts on body, the different manifestations of integrally-regulated effect.
In present embodiment, eliminating stagnation nodules of the breast cream is applied to ovarian cyst patient's clinical trial:
This group 100 examples are all from the OILFIELDS GENEROL HOSPITAL IN DAGING special outpatient clinic, and the age is at 28～46 years old, 30 years old mean age; The course of disease 6 months～2 years.Be divided at random treatment group 50 example and matched group 50 examples, learn and process without significant difference (P＞0.05) by statistics on age, the course of disease, have comparability for 2 groups.
Before treatment: medical because of lower abdomen pendant pain, lumbago or menoxenia, indagation is made a definite diagnosis in conjunction with ultrasound diagnosis through gynecological, and, through 2 or 2 above menstrual cycle checks, has ovarian cyst, and require expectant treatment.B ultrasonic prompting ovarian cyst diameter is 2～5cm, and majority has opaque dark area of fluid, or no echo area, and the gynecologial examination adnexa can touch capsule enclosed mass, movable good, smooth surface.Larger or the required higher level's examination in hospital of older patient ovarian tumor markers of ovarian cyst etc., in order to get rid of malignant tumor of ovary.
Medication and Therapeutic Method:
Treatment group: eliminating stagnation nodules of the breast patch is in Yinjiao point (one-inch place under umbilicus), and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks continuously 28 days.
Matched group: oral Ramulus Cinnamomi Poria pill, 1 ball, 1～2 time on the one.
Clinical efficacy
Treatment group 50 examples:
Recovery from illness patient 45 examples: show as transference cure, lower abdomen, waist and pain in the hypochondrium disappear, menstruation extremely, measure medium, through the disappearance of B ultrasonic check lump;
Patient's 5 examples that sb.'s illness took a favorable turn: show as transference cure or alleviate, lower abdomen, waist and pain in the hypochondrium disappear or alleviate, the rare clot of menstruation, and lump dwindles more than 1/3～2/3.
Matched group 50 examples:
Recovery from illness patient 20 examples: show as transference cure, lower abdomen, waist and pain in the hypochondrium disappear, menstruation extremely, measure medium, through the disappearance of B ultrasonic check lump;
Patient's 10 examples that sb.'s illness took a favorable turn: show as transference cure or alleviate, lower abdomen, waist and pain in the hypochondrium disappear or alleviate, the rare clot of menstruation, and lump dwindles more than 1/3～2/3.
Invalid 20 examples: symptom is without improvement.
Conclusion: the effect for the treatment of group treatment ovarian cyst is better than matched group, and easy to use, patient's no pain.
Claims (2)
1. the application of eliminating stagnation nodules of the breast cream in the primary dysmenorrhea treatment, it is characterized in that the application of eliminating stagnation nodules of the breast cream in the primary dysmenorrhea treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and menstruation started to stick in front 3 days, every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks to menstruation the 4th day.
2. the application of eliminating stagnation nodules of the breast cream in the ovarian cyst treatment is characterized in that the application of eliminating stagnation nodules of the breast cream in the ovarian cyst treatment: eliminating stagnation nodules of the breast patch is spread on Yinjiao point, and every day 1 time, each 1 pastes, and sticks more than 12 hours, sticks continuously 28 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103560975A CN103394043A (en) | 2013-08-15 | 2013-08-15 | Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103560975A CN103394043A (en) | 2013-08-15 | 2013-08-15 | Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103394043A true CN103394043A (en) | 2013-11-20 |
Family
ID=49557896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103560975A Pending CN103394043A (en) | 2013-08-15 | 2013-08-15 | Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103394043A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593599A (en) * | 2004-06-23 | 2005-03-16 | 齐齐哈尔鹤翔制药有限责任公司 | Ointment for dispersing breast nodules and preparation method thereof |
| CN101147798A (en) * | 2007-08-28 | 2008-03-26 | 武修春 | Galactophore paste and its preparing process |
-
2013
- 2013-08-15 CN CN2013103560975A patent/CN103394043A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593599A (en) * | 2004-06-23 | 2005-03-16 | 齐齐哈尔鹤翔制药有限责任公司 | Ointment for dispersing breast nodules and preparation method thereof |
| CN101147798A (en) * | 2007-08-28 | 2008-03-26 | 武修春 | Galactophore paste and its preparing process |
Non-Patent Citations (3)
| Title |
|---|
| 《黑龙江鹤翔制药有限公司》: "《地方食品药品监督机构改革年底前完成 三定方案今日出台》", 《HTTP://WWW.HLJHXZY.COM/HTML/2013/INDUSTRYNEWS_0724/773.HTML》, 24 July 2013 (2013-07-24) * |
| 王秋玲等: "《散结乳癖膏对卵巢囊肿大鼠血清E2_P的影响》", 《黑龙江科技信息》, no. 10, 5 April 2013 (2013-04-05), pages 60 - 61 * |
| 药源网: "《散结乳癖膏》", 《HTTP://WWW.YAOPINNET.COM/ZHAOSHANG/Y22/YY138822.HTM》, 24 February 2011 (2011-02-24) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103845348B (en) | 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine | |
| CN102258685B (en) | Compound traditional Chinese medicine for treating diminished ovarian reserve and application | |
| Jiang et al. | Treatment of Chinese herbal medicine for female infertility | |
| CN104857478A (en) | Medical composition for treating hysteromyoma and preparation method of medical composition | |
| CN106692946A (en) | Composition for relieving vaginal relaxation, and preparation and preparing method thereof | |
| CN102727677B (en) | Novel compound donkey-hide glue extract powder formula, preparation and application of novel compound donkey-hide glue extract powder formula | |
| CN107982331A (en) | A kind of Chinese medicine preparation essential oil of the external curing proliferation of mammary gland | |
| Hartman | Menstruation inhibiting action of testosterone | |
| CN102908579B (en) | Traditional Chinese medicine preparation for treating gynecological diseases, liver diseases and prostatitis and preparation method of traditional Chinese medicine preparation | |
| CN102614487A (en) | Plaster for treatment of prostate and uracratia | |
| CN103055083B (en) | Chinese medicine for treating women dysmenorrhea and preparation method of external patch of Chinese medicine | |
| CN103585573B (en) | Oral medicine for treating hysteromyoma | |
| CN102309651A (en) | New use of compound traditional Chinese medicine | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN103071018B (en) | Traditional Chinese medicine preparation for treating early habitual abortion | |
| CN104740536A (en) | Pharmaceutical composition for treating endometriosis (EMT) and adenomyosis (AM) and preparation method and use thereof | |
| CN104548050A (en) | Composition as well as preparation method and application thereof | |
| CN103394043A (en) | Application of stasis-removing paste for nodules of breast for treatment of primary dysmenorrheal and ovarian cyst | |
| CN108498705A (en) | Vagina doubts glue bolt and preparation method thereof | |
| CN102579761A (en) | Application of traditional Chinese medicine beauty composition in preparation of medicament for adjusting women hormonal equilibrium | |
| CN102949467A (en) | Medicinal composition for treating chronic pelvic inflammation caused by dampness and hotness obstruction | |
| CN102641277B (en) | Ointment for treating gynaopathy and dermatoses and preparation method thereof | |
| CN103520487B (en) | A kind of purposes of pharmaceutical composition | |
| CN108310363A (en) | Applications of the CRM197 in the drug for preparing treatment polycystic ovary syndrome | |
| CN102861185A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131120 |